“In a late-stage trial, Eli Lilly’s experimental obesity drug retatrutide delivered some of the best weight-loss results ever seen. Patients on the highest dose lost nearly 29 percent of their body weight over 68 weeks. Across all treated participants, average weight loss was about 24 percent, appearing to outperform currently approved drugs like semaglutide and tirzepatide,” reports The Doomslayer.
CNBC explains that Eli Lilly’s next-generation obesity drug delivered:
the highest weight loss yet in a late-stage trial while reducing knee arthritis pain, clearing the first of several upcoming studies on the weekly injection.
The highest dose of the drug helped patients with obesity and a type of knee arthritis lose an average of 23.7% of their body weight at 68 weeks, when analyzing all participants, including those who discontinued treatment. When evaluating only patients who stayed on the drug, the highest dose delivered 28.7% weight loss on average….some patients lost so much weight that they decided to drop out of the trial…Eli Lilly appears to be positioning the drug strategically for people with severe obesity, or a body mass index above 35 or 40….
It is the first late-stage data on retatrutide, which works differently from existing injections and appears to be more effective. Eli Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill. But it’s still unclear when the drug could enter the market…
Retatrutide also met the trial’s other main goal of reducing pain from knee osteoarthritis – a common condition that wears down the joint’s cartilage and leads to pain and stiffness – by up to 62.6% on average.
Obesity has finally stopped rising in America, thanks to anti-obesity drugs.
But fat acceptance and misinformation have fueled rising obesity rates. In 2021, Cosmopolitan magazine falsely suggested obesity is healthy. A fat-shaming “expert” went to work for San Francisco to normalize obesity.
